{"nctId":"NCT00156910","briefTitle":"A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches","startDateStruct":{"date":"2006-02"},"conditions":["Migraine Disorders"],"count":679,"armGroups":[{"label":"botulinum toxin Type A","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum Toxin Type A"]},{"label":"Placebo (saline)","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo (saline)"]}],"interventions":[{"name":"Botulinum Toxin Type A","otherNames":["BOTOXÂ®"]},{"name":"Placebo (saline)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Frequent migraine (\\>=15 headache days per month)\n* \\>=4 distinct headache episodes lasting \\>=4 hours\n* \\>=50% of baseline headache days migraine/probable migraine days\n\nExclusion Criteria:\n\n* Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype\n* Any medical condition that puts the patient at increased risk with exposure to BOTOX\n* Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache\n* Use of prophylactic headache medication within 28 days prior to week -4\n* Unremitting headache lasting continuously throughout the 4-week baseline period\n* Known or suspected Temporomandibular Disorders (TMD)\n* Diagnosis of fibromyalgia\n* Beck depression inventory score \\>24 at week-4\n* Psychiatric problems that may have interfered with study participation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Frequency of Headache Episodes","description":"Mean change from baseline in frequency (number) of headache episodes during the 28 day period ending with Week 24. Headache episode defined as patient-reported headache with a start and stop time indicating that the pain lasted \\>= 4 continuous hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":"5.23"},{"groupId":"OG001","value":"13.4","spread":"5.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.2","spread":"5.27"},{"groupId":"OG001","value":"-5.3","spread":"5.85"}]}]}]},{"type":"SECONDARY","title":"Change in Frequency of Headache Days","description":"Mean change from baseline in frequency (number) of headache days during the 28 day period ending with Week 24. Headache day defined as a calendar day \\[00:00 to 23:59\\] for which the patient reported \\>= 4 continuous hours of headache","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":"3.73"},{"groupId":"OG001","value":"19.8","spread":"3.71"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.8","spread":"6.57"},{"groupId":"OG001","value":"-6.4","spread":"6.69"}]}]}]},{"type":"SECONDARY","title":"Change in Frequency of Acute Headache Pain Medication Intakes","description":"Mean change from baseline in frequency (number) of acute headache pain medication intakes during the 28 day period ending with Week 24. Medication intakes defined as the number of times a patient took acute headache pain medication regardless of dose or type/number of medications taken at the same time.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":"19.27"},{"groupId":"OG001","value":"30.4","spread":"22.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"18.67"},{"groupId":"OG001","value":"-10.4","spread":"18.54"}]}]}]},{"type":"SECONDARY","title":"Change in Frequency of Migraine/Probable Migraine Headache Days","description":"Mean change from baseline in frequency (number) of migraine/probable migraine headache days during the 28 day period ending with Week 24. Headache day defined as a calendar day with \\>= 4 continuous hours of headache meeting ICHD-II criteria for migraine or probable migraine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":"4.04"},{"groupId":"OG001","value":"19.1","spread":"4.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.6","spread":"6.51"},{"groupId":"OG001","value":"-6.1","spread":"6.78"}]}]}]},{"type":"SECONDARY","title":"Change in Frequency of Migraine/Probable Migraine Headache Episodes","description":"Mean change from baseline in frequency (number) of migraine/probable migraine headache episodes during the 28 day period ending with Week 24. Headache episode defined as patient-reported headache with a start and stop time indicating that the pain lasted \\>= 4 continuous hours and met ICHD-II criteria for migraine or probable migraine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"5.06"},{"groupId":"OG001","value":"12.7","spread":"5.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"5.06"},{"groupId":"OG001","value":"-4.9","spread":"5.74"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":42,"n":624},"commonTop":["Neck pain","Sinusitis","Upper respiratory tract infection","Nasopharyngitis","Muscular weakness"]}}}